Understand the source comparison
ARA-290 Before and After: Research Model Comparison
Different injury models reveal different facets of ARA-290's tissue-protective capacity. The table below compares key research applications, typical dosing regimens, measurable endpoints, and timeline to observable before and after differences. Diabetic Neurop
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different injury models reveal different facets of ARA-290's tissue-protective capacity. The table below compares key research applications, typical dosing regimens, measurable endpoints, and timeline to observable before and after differences.
- Diabetic Neuropathy (STZ-Induced)
- 1–4 mg/kg SC daily × 14–28 days
- Nerve conduction velocity, IENFD
- 14–28 days
- Consistent 15–25% NCV improvement; requires baseline electrophysiology
- Excisional Wound Healing
- 0.5–2 mg/kg SC daily × 10–14 days
- Wound closure %, histological markers
- 7–14 days
- 30–40% faster closure; angiogenesis visible by day 7
- Cardiac Ischemia-Reperfusion
- 0.3–1 mg/kg IV at reperfusion
- Infarct size (TTC staining), ejection fraction
- 24 hours (infarct), 7–28 days (function)
- Reduced infarct size by 30–50%; preserved EF at 28 days
- Corneal Injury
- Topical 10–50 μg/mL BID × 7 days
- Epithelial defect area, corneal opacity score
- 3–7 days
- Faster re-epithelialization; reduced stromal inflammation
- Chemotherapy-Induced Neuropathy
- 2–4 mg/kg SC 3×/week × 4 weeks
- Mechanical allodynia threshold, cold sensitivity
- Dose-dependent pain threshold improvement; prophylactic dosing superior
- Renal Ischemia-Reperfusion
- 1 mg/kg IV at reperfusion
- Serum creatinine, tubular injury score
- 24–72 hours
- 40–60% reduction in tubular necrosis; transient creatinine benefit
- The diabetic neuropathy model remains the most clinically translatable—this is where ARA-290 advanced to phase II human trials. The consistent observation across rodent, rabbit, and human studies is that IRR activation partially reverses small fiber loss and improves pain perception, but doesn't fully restore baseline nerve density. This suggests ARA-290 halts progressive degeneration and supports limited regeneration rather than inducing complete repair.
- Wound healing models show the most dramatic before and after visual differences, making them popular for proof-of-concept studies. However, translation to chronic human wounds (diabetic ulcers, pressure ulcers) has been less successful than the rodent data predicted. The likely explanation: rodent wounds heal by contraction (myofibroblast-driven), while human wounds heal primarily by re-epithelialization. ARA-290's effects on keratinocyte migration may be species-dependent or require higher local concentrations than systemic dosing achieves.
- Cardiac ischemia-reperfusion research demonstrates ARA-290's protective capacity when administered peri-injury, but it's not a rescue therapy for established damage. The peptide must be present during the acute inflammatory phase—within 30 minutes of reperfusion—to significantly reduce infarct size. Delayed administration at 6 or 24 hours post-reperfusion shows minimal benefit, reinforcing that IRR activation prevents injury propagation rather than reversing established necrosis.